Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 152,345	$ 198,955
Short-term investments	847,720	862,941
Accounts receivable	28,871	38,889
Inventory	14,616	15,292
Other current assets	12,596	21,928
Total current assets	1,056,148	1,138,005
Long-term investments	57,397	136,662
Property, plant and equipment, net	58,599	59,662
Operating lease right-of-use assets	122,362	126,476
Goodwill	76,501	76,501
Other assets	344	1,461
Total assets	1,371,351	1,538,767
Current liabilities:
Accounts payable	19,701	22,139
Accrued compensation	28,665	14,532
Accrued clinical trial expenses	41,085	44,207
Accrued contract manufacturing expenses	8,392	11,310
Other accrued expenses	16,404	9,676
Operating lease liabilities, current portion	16,776	13,915
Total current liabilities	131,023	115,779
Operating lease liabilities, less current portion	131,658	136,373
Development derivative liability	11,607	0
Liabilities related to the sales of future royalties, net	188,072	200,340
Other long-term liabilities	4,016	8,980
Total liabilities	466,376	461,472
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2021 or December 31, 2020	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 183,773 shares and 180,091 shares outstanding at June 30, 2021 and December 31, 2020, respectively	18	18
Capital in excess of par value	3,466,001	3,388,730
Accumulated other comprehensive loss	(3,400)	(2,295)
Accumulated deficit	(2,557,644)	(2,309,158)
Total stockholders’ equity	904,975	1,077,295
Total liabilities and stockholders’ equity	$ 1,371,351	$ 1,538,767